Target intelligence / Profile preview

60S acidic ribosomal protein P0 and P1 (RPLP0/RPLP1)

Target
RPLP0/RPLP1
Molecular classification
Ribosomal protein, Phosphoprotein, Translation factor recruiter
01

Overview

The 60S acidic ribosomal proteins P0 and P1 are essential components of the eukaryotic ribosome's lateral stalk, a dynamic structure critical for protein biosynthesis [1, 3]. P0 serves as the anchor for the stalk, binding directly to the 28S ribosomal RNA, while P1 (along with P2) forms heterodimers that attach to P0 to complete the pentameric P-complex [5, 12]. This stalk is primarily responsible for the recruitment and activation of GTP-dependent translation elongation factors, such as eEF-1 and eEF-2, which are necessary for the movement of the ribosome along mRNA [8, 13]. In clinical contexts, these proteins are significant autoantigens in Systemic Lupus Erythematosus (SLE), where the presence of anti-ribosomal P antibodies is a highly specific marker for the disease and its neuropsychiatric manifestations [2, 13]. Furthermore, P0 and P1 are frequently overexpressed in various malignancies, including breast, liver, and lung carcinomas, where they contribute to increased translational capacity and tumor progression [1, 9]. They also serve as the critical docking site for ribosome-inactivating toxins like ricin and Shiga toxin, which exploit the P-stalk to access the sarcin-ricin loop and halt cellular protein production [13, 17]. Research into targeting these proteins for cancer therapy is ongoing, though their essential role in global translation presents significant challenges for achieving therapeutic selectivity [9, 15].

Other names
60S acidic ribosomal protein P060S acidic ribosomal protein P1Ribosomal protein lateral stalk subunit P0Ribosomal protein lateral stalk subunit P1Acidic ribosomal phosphoprotein P0Acidic ribosomal phosphoprotein P1RPP0RPP1L10EL12PP-stalk proteins
02

Mechanism of action

Toxins like ricin and Shiga toxin bind to the conserved C-terminal domain of the P-stalk proteins to gain access to the sarcin-ricin loop of the 28S rRNA, where they exert N-glycosidase activity to inhibit translation [13, 17].

03

Biological functions

Protein synthesisTranslation elongationGTPase activationRecruitment of translation factorsmRNA translation regulation
04

Disease associations

CancerSystemic lupus erythematosusInfectious diseaseMalaria
05

Safety considerations

Systemic toxicity due to inhibition of essential protein synthesisPotential for triggering or exacerbating autoimmune responses
06

Interacting drugs

Ricin

1 more in the full profile.

07

Biomarkers

Anti-ribosomal P antibodies

Beyond the preview

Go deeper on 60S acidic ribosomal protein P0 and P1 (RPLP0/RPLP1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 60S acidic ribosomal protein P0 and P1 (RPLP0/RPLP1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call